<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CTIC</title>
	<atom:link href="http://www.stockbloghub.com/tag/ctic/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CTIC) Cell Therapeutics Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/13/ctic-cell-therapeutics-incorporated-bull-of-the-day/85021</link>
		<comments>http://www.stockbloghub.com/2011/10/13/ctic-cell-therapeutics-incorporated-bull-of-the-day/85021#comments</comments>
		<pubDate>Thu, 13 Oct 2011 16:31:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85021</guid>
		<description><![CDATA[In late September, Cell Therapeutics (CTIC) announced that a second independent radiologic review of data from the pivotal trial PIX301 of lead drug pixantrone for aggressive NHL confirmed the statistical significance of response and progression endpoints. With this positive development, we believe pixantrone is getting closer to approval. We are encouraged by the FDA&#8217;s decision to allow Cell Therapeutics to re-submit the NDA for pixantrone for review without the need for an additional trial. We are therefore upgrading our rating on the stock from Neutral to Outperform. Cell Therapeutics second most advanced pipeline candidate, Opaxio, is being studied as a potential maintenance therapy for women with advanced ovarian cancer who achieve complete remission following first-line therapy with paclitaxel and carboplatin. The phase III study, GOG0212, has already enrolled more than ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/13/ctic-cell-therapeutics-incorporated-bull-of-the-day/85021/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Quarterly Earnings Lag &#8211; Company Pares Loss</title>
		<link>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335</link>
		<comments>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:45:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80335</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) suffered a net loss of 14 cents per share in the second quarter of 2011, compared with a net loss of 46 cents (excluding special items) per share in the year-ago quarter. The narrower loss per share in the reported quarter was due to lower operating expenses and lower deemed dividend paid to preferred shareholders. The Zacks Consensus Estimate for the reported quarter was a loss of 12 cents per share. Cell Therapeutics did not generate any revenue during the reported quarter versus $0.029 million in the second quarter of 2010. Total operating expense in the quarter declined 15% to $16.9 million. Pipeline Update In June this year, Cell Therapeutics met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/ctic-cell-therapeutics-quarterly-earnings-lag-company-pares-loss/80335/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CPO) Company News for July 01, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/07/01/cpo-company-news-for-july-01-2011-corporate-summary/78203</link>
		<comments>http://www.stockbloghub.com/2011/07/01/cpo-company-news-for-july-01-2011-corporate-summary/78203#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:39:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[Processed & Packaged Goods]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[Corn Products International Inc]]></category>
		<category><![CDATA[CPO]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[First Solar Inc.]]></category>
		<category><![CDATA[FSLR]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Lloyds Banking Group plc]]></category>
		<category><![CDATA[LMT]]></category>
		<category><![CDATA[Lockheed Martin Corporation]]></category>
		<category><![CDATA[LULU]]></category>
		<category><![CDATA[Lululemon Athletica Inc]]></category>
		<category><![CDATA[LYG]]></category>
		<category><![CDATA[NetApp Inc.]]></category>
		<category><![CDATA[NTAP]]></category>
		<category><![CDATA[USANA Health Sciences Inc.]]></category>
		<category><![CDATA[USNA]]></category>
		<category><![CDATA[WOR]]></category>
		<category><![CDATA[Worthington Industries Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78203</guid>
		<description><![CDATA[•    Shares of Cell Therapeutics, Inc. (NASDAQ:CTIC) declined by 19.64% after the cancer drug developer said it was selling Series 13 preferred stock worth $30 million •    Vitamin maker USANA Health Sciences Inc.’s (NYSE:USNA) shares rose 7.90% after the company&#8217;s projected second-quarter profits came in above the Street&#8217;s estimates •    The Board of directors of Worthington Industries Inc. (NYSE:WOR) has authorized the repurchase of an additional 10 million shares of the company. The metal processor also increased its quarterly dividend payout to investors •    Share prices of Lockheed Martin (NYSE:LMT) rose marginally after the defense supplier said it would initiate a cost-cutting program by laying off 1500 employees in its Aeronautics business area which will help increase the operational efficiency of the company&#8217;s products •    The U.S. Department of Energy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/cpo-company-news-for-july-01-2011-corporate-summary/78203/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Analyst Mintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315</link>
		<comments>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:03:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77315</guid>
		<description><![CDATA[We are maintaining a Neutral recommendation on Cell Therapeutics Inc. (CTIC) with a target price of $2.25. Cell Therapeutics Inc. based in Seattle, Washington, is focused on developing drugs for cancer. The company’s lead pipeline candidate, pixantrone, is being developed for the treatment of hematologic malignancies and solid tumors. In December 2010, Cell Therapeutics filed an appeal against the decision of the FDA in April 2010 to deny approval to pixantrone for the treatment of relapsed, aggressive non-Hodgkin&#8217;s lymphoma, or NHL, in patients who have not responded to other treatment options. The approval was denied due to concerns that the late stage trial PIX301 (which formed the basis of the NDA filing) had not sufficiently proved the effectiveness of the drug. The FDA asked Cell Therapeutics to conduct an additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/ctic-cell-therapeutics-analyst-mintains-neutral-on-shares/77315/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Posts Positive Pixantrone Data</title>
		<link>http://www.stockbloghub.com/2011/06/22/ctic-cell-therapeutics-posts-positive-pixantrone-data/76854</link>
		<comments>http://www.stockbloghub.com/2011/06/22/ctic-cell-therapeutics-posts-positive-pixantrone-data/76854#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:21:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76854</guid>
		<description><![CDATA[Cell Therapeutics Inc. (CTIC) recently announced that data from an early stage study of its lead pipeline candidate, pixantrone, for an additional indication, was published in Cancer, an online journal. The study (n=28) tested the efficacy and safety of pixantrone as a combination therapy with fludarabine, dexamethasone and Biogen/Roche’s (BIIB/RHHBY) Rituxan (FPD-R) for the treatment of relapsed or refractory indolent non-hodgkin’s lymphoma (INHL). In this study pixantrone was substituted for mitoxantrone in the FPD-R regimen compared to the standard FND-R regimen. The data revealed that pixantrone in combination with fludarabine, dexamethasone and Rituxan was highly active in patients with relapsed or refractory INHL and produced complete response (CR) in 63% of patients. The overall response rate (ORR) was 89%. The response lasted for 40 months in the longest responding patient ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/ctic-cell-therapeutics-posts-positive-pixantrone-data/76854/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Set to Resubmit Pixantrone NDA</title>
		<link>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603</link>
		<comments>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:50:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76603</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) recently met with the Division of Oncology Drug Products (the DODP) of the US Food and Drug Administration (FDA) and received guidance for resubmission of the new drug application (NDA) for its lead pipeline candidate pixantrone. Pixantrone has been developed for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. The company is also looking for accelerated approval of the NDA based on data from the PIX301 study. The meeting follows the early May decision of the Office of New Drugs (OND) of the FDA allowing the company to re-submit the NDA for pixantrone for review without the need for an additional trial. The OND recommended Cell Therapeutics to conduct an additional independent radiologic review utilizing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/ctic-cell-therapeutics-set-to-resubmit-pixantrone-nda/76603/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HNAB) Hana Bioscience Encouraging Phase II Results</title>
		<link>http://www.stockbloghub.com/2010/11/09/hnab-hana-bioscience-encouraging-phase-ii-results/58616</link>
		<comments>http://www.stockbloghub.com/2010/11/09/hnab-hana-bioscience-encouraging-phase-ii-results/58616#comments</comments>
		<pubDate>Tue, 09 Nov 2010 18:28:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[Crane Company]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[Hana Biosciences Inc]]></category>
		<category><![CDATA[HNAB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58616</guid>
		<description><![CDATA[Written by Grant Zeng, CFA Hana Biosciences Inc. ( HNAB ) A decent pipeline with late stage candidates&#8230; South San Francisco, CA based Hana Biosciences, Inc. (Hana) is a late development stage biopharmaceutical company which is focused on two cancer care areas: cancer therapeutics and cancer supportive care. The company’s lead cancer therapeutic candidate is Marqibo (vincristine sulfate liposome injection), a novel, targeted Optisome encapsulated formulation product candidate of the FDA-approved anticancer drug vincristine, for the treatment of relapsed/refractory adult acute lymphoblastic leukemia (ALL). Hana presented results from the registration-enabling Phase II clinical trial (rALLY) of Marqibo for ALL in June 2010 at the ASCO meeting. The data were compelling. Marqibo was administered as third-, fourth-, fifth-, and sixth-line single-agent therapy for ALL patients. The trial achieved 35% overall response rate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/09/hnab-hana-bioscience-encouraging-phase-ii-results/58616/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Reports Narrower Third Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/11/07/ctic-cell-therapeutics-reports-narrower-third-quarter-loss/58320</link>
		<comments>http://www.stockbloghub.com/2010/11/07/ctic-cell-therapeutics-reports-narrower-third-quarter-loss/58320#comments</comments>
		<pubDate>Sun, 07 Nov 2010 20:17:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58320</guid>
		<description><![CDATA[Cell Therapeutics Inc. (CTIC) suffered a net loss of $15.6 million (2 cents per share) in the third quarter of 2010 as opposed to the net loss of $48.8 million (9 cents per share) suffered in the year-ago quarter. The narrower loss was primarily attributable to lower operating expenses, lower deemed dividends on preferred stock and a one-time milestone modification expense which was taken care of in the previous year. Excluding deemed dividends on preferred stock, foreign exchange effect and a one-time milestone modification expense, loss at Cell Therapeutics came in at $15.2 million or approximately 2 cents per share, against $28.8 million or 5 cents in the year ago quarter. The Zacks Consensus Estimate hinted at a loss of 6 cents per share for the quarter. Cell Therapeutics did ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/07/ctic-cell-therapeutics-reports-narrower-third-quarter-loss/58320/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Analyst Cuts Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305</link>
		<comments>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305#comments</comments>
		<pubDate>Thu, 07 Oct 2010 23:28:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54305</guid>
		<description><![CDATA[We are downgrading Cell Therapeutics, Inc. (CTIC) to Underperform from Neutral with a price target of $0.25 primarily due to the uncertainty surrounding the US approval of its lead candidate, pixantrone. Pixantrone (proposed trade name: Pixuvri), is currently under development for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. Cell Therapeutics Inc., based in Seattle, Washington, is focused on developing drugs for cancer. The company received a setback in April 2010, when the US Food and Drug Administration (FDA) denied approval to pixantrone and issued a complete response letter (CRL) based on issues related to the study design. The FDA asked Cell Therapeutics to conduct an additional trial to determine the safety and efficacy of pixantrone. In August ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-analyst-cuts-shares-to-underperform/54305/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-bear-of-the-day/54250</link>
		<comments>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-bear-of-the-day/54250#comments</comments>
		<pubDate>Thu, 07 Oct 2010 16:13:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54250</guid>
		<description><![CDATA[We are downgrading Cell Therapeutics (CTIC) to Underperform from Neutral, primarily due to the uncertainty surrounding the approval of its lead candidate, pixantrone for aggressive NHL in the US. Cell Therapeutics&#8217; future is dependent on pixantrone since it does not have any other candidate, apart from Opaxio, to fall back on, if the company&#8217;s lead candidates are not approved. Furthermore, even if pixantrone manages to hit the market, it will face intense competition from established players. Meanwhile, although the company has brought down its debt burden by converting it to common stock, we remain concerned about the significant dilution in shareholder value. CELL THERAPEUT (CTIC): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/07/ctic-cell-therapeutics-bear-of-the-day/54250/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Announces Challenge to US Food and Drug Administration Decision</title>
		<link>http://www.stockbloghub.com/2010/09/14/ctic-cell-therapeutics-announces-challenge-to-us-food-and-drug-administration-decision/51535</link>
		<comments>http://www.stockbloghub.com/2010/09/14/ctic-cell-therapeutics-announces-challenge-to-us-food-and-drug-administration-decision/51535#comments</comments>
		<pubDate>Wed, 15 Sep 2010 04:02:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[PharmAthene Inc]]></category>
		<category><![CDATA[PIP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=51535</guid>
		<description><![CDATA[Recently, Cell Therapeutics Inc. (CTIC) announced that it will appeal against the decision of the US Food and Drug Administration (FDA) to deny approval to the company’s lead candidate, pixantrone. The candidate is being developed for the treatment of relapsed or refractory aggressive non-Hodgkin&#8217;s lymphoma (NHL) in patients who have not responded to other treatment options. In April 2010, the FDA denied approval to pixantrone, and issued a complete response letter (CRL) based on issues related to the study design. The FDA asked Cell Therapeutics to conduct an additional trial to determine the safety and efficacy of pixantrone. The company intends to file an appeal against the decision under the FDA&#8217;s formal dispute resolution process. The decision was based on the fact that management believes there are no approved or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/14/ctic-cell-therapeutics-announces-challenge-to-us-food-and-drug-administration-decision/51535/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Stock Issuance Dilutes Shareholder Value</title>
		<link>http://www.stockbloghub.com/2010/05/18/ctic-cell-therapeutics-stock-issuance-dilutes-shareholder-value/37528</link>
		<comments>http://www.stockbloghub.com/2010/05/18/ctic-cell-therapeutics-stock-issuance-dilutes-shareholder-value/37528#comments</comments>
		<pubDate>Tue, 18 May 2010 15:38:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37528</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) recently decided to exchange up to 60 million shares of its common stock for $30 million of notes. Liquidity crisis at the company continues to remain a major concern for us. Earlier, in April 2010, the company raised $18.5 million through preferred stock and warrants. Although Cell Therapeutics has taken several steps to reduce the burn rate, its cash crunch will continue for the time being. During 2009, Cell Therapeutics reduced its debt burden considerably. However, the company’s policy to reduce debt level by converting into common stock dilutes shareholder value. The liquidity crisis at Cell Therapeutics has become more prominent since its New Drug Application for lead candidate, Pixuvri was denied. The company has been seeking approval for the drug to treat relapsed or refractory aggressive ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/18/ctic-cell-therapeutics-stock-issuance-dilutes-shareholder-value/37528/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Announces Workforce Reduction</title>
		<link>http://www.stockbloghub.com/2010/04/18/ctic-cell-therapeutics-announces-workforce-reduction/34103</link>
		<comments>http://www.stockbloghub.com/2010/04/18/ctic-cell-therapeutics-announces-workforce-reduction/34103#comments</comments>
		<pubDate>Mon, 19 Apr 2010 01:30:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34103</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) recently reduced its workforce by 36 employees. The reduction in staff strength along with the elimination of other planned expenses is likely to result in savings of about $16 million in 2010. The company now expects operating expenses in 2010 to be approximately $60 million, a 21% reduction from its earlier projection. Earlier this month, Cell Therapeutics received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for Pixuvri (pixantrone dimaleate), its lead pipeline candidate. This setback led the company take the decision on retrenchment to reduce expenses. The company was seeking approval for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. Although Cell Therapeutics will request a meeting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/18/ctic-cell-therapeutics-announces-workforce-reduction/34103/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics&#8217; Pixantrone Denied FDA Approval</title>
		<link>http://www.stockbloghub.com/2010/04/09/ctic-cell-therapeutics-pixantrone-denied-fda-approval/33336</link>
		<comments>http://www.stockbloghub.com/2010/04/09/ctic-cell-therapeutics-pixantrone-denied-fda-approval/33336#comments</comments>
		<pubDate>Fri, 09 Apr 2010 21:23:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33336</guid>
		<description><![CDATA[In a major setback, Cell Therapeutics (CTIC) has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for Pixuvri (pixantrone dimaleate). The company has been seeking approval for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) in patients who have not responded to other treatment options. However, this decision was expected as last month the FDA’s Oncologic Drugs Advisory Committee had unanimously decided against the approval of the candidate, citing the lack of sufficient clinical data. Some issues were raised by the FDA related to the study design at the advisory committee meeting. The same concerns led the FDA to take this decision. The study that opened in June 2004 sought to enroll 320 patients. However, the enrollment was challenging and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/09/ctic-cell-therapeutics-pixantrone-denied-fda-approval/33336/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Seeks FDA Approval of non-Hodgkin’s Lymphoma Candidate</title>
		<link>http://www.stockbloghub.com/2010/04/05/ctic-cell-therapeutics-seeks-fda-approval-of-non-hodgkin%e2%80%99s-lymphoma-candidate/32833</link>
		<comments>http://www.stockbloghub.com/2010/04/05/ctic-cell-therapeutics-seeks-fda-approval-of-non-hodgkin%e2%80%99s-lymphoma-candidate/32833#comments</comments>
		<pubDate>Tue, 06 Apr 2010 04:17:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32833</guid>
		<description><![CDATA[April is crucial for Cell Therapeutics (CTIC), as the US Food and Drug Administration (FDA) decides on the approvability of pixantrone by April 23, 2010. The company is seeking approval of its lead candidate, pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin’s Lymphoma (NHL) in patients who have not responded to other treatment options. However, we are not quite optimistic about the product gaining approval. Last month, the FDA’s Oncologic Drugs Advisory Committee unanimously decided against the approval of the candidate, citing lack of sufficient clinical data. Although the FDA is not bound to follow the panel’s decision, it generally does so. It is quite unlikely that the agency would approve a drug that has been voted against unanimously. Certain issues raised by the FDA reviewers related to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/05/ctic-cell-therapeutics-seeks-fda-approval-of-non-hodgkin%e2%80%99s-lymphoma-candidate/32833/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Suffers as FDA Panel Rules Against Pixantrone</title>
		<link>http://www.stockbloghub.com/2010/03/29/ctic-cell-therapeutics-suffers-as-fda-panel-rules-against-pixantrone/31703</link>
		<comments>http://www.stockbloghub.com/2010/03/29/ctic-cell-therapeutics-suffers-as-fda-panel-rules-against-pixantrone/31703#comments</comments>
		<pubDate>Mon, 29 Mar 2010 21:25:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31703</guid>
		<description><![CDATA[In a major disappointment for Cell Therapeutics’ (CTIC), the US Food and Drug Administration&#8217;s (FDA) Oncologic Drugs Advisory Committee unanimously decided against the approval of the company’s lead candidate pixantrone, citing lack of sufficient clinical data. Cell Therapeutics is seeking approval of pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin’s Lymphoma (NHL) in patients who have not responded to other treatment options. Although the FDA is not bound to follow the panel’s decision, it generally does so. It is quite unlikely that the agency would approve a drug that has been voted against unanimously. A final decision on pixantrone should be taken by April 23. We were concerned about pixantrone’s approval due to certain issues raised by the FDA reviewers related to the study design. The study that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/ctic-cell-therapeutics-suffers-as-fda-panel-rules-against-pixantrone/31703/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Gets Good News From the FDA</title>
		<link>http://www.stockbloghub.com/2010/03/08/ctic-cell-therapeutics-gets-good-news-from-the-fda/30061</link>
		<comments>http://www.stockbloghub.com/2010/03/08/ctic-cell-therapeutics-gets-good-news-from-the-fda/30061#comments</comments>
		<pubDate>Tue, 09 Mar 2010 00:35:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30061</guid>
		<description><![CDATA[In a positive development, Cell Therapeutics (CTIC) announced that the US Food and Drug Administration (FDA) has completed its inspection of the company’s manufacturing facility in Italy and found it to be compliant with all the required norms. The facility manufactures Cell Therapeutics’ Pixuvri (pixantrone), which is currently under FDA review. Cell Therapeutics is seeking FDA approval of pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin’s Lymphoma (NHL) in patients who have not responded to other treatment options. A final decision on the drug should be taken by April 23. Pixantrone was supposed to be reviewed by the Oncologic Drugs Advisory Committee in a meeting scheduled for February 10, which had to be postponed due to bad weather conditions in the Washington region. A new review date of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/08/ctic-cell-therapeutics-gets-good-news-from-the-fda/30061/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics&#8217; Drug Approval Delayed</title>
		<link>http://www.stockbloghub.com/2010/02/12/ctic-cell-therapeutics-drug-approval-delayed/27742</link>
		<comments>http://www.stockbloghub.com/2010/02/12/ctic-cell-therapeutics-drug-approval-delayed/27742#comments</comments>
		<pubDate>Fri, 12 Feb 2010 17:47:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27742</guid>
		<description><![CDATA[The wait for the approval of Cell Therapeutics’ (CTIC) drug, Pixuvri (pixantrone) is far from over. Recently, the US Food and Drug Administration (FDA) announced that the Oncologic Drugs Advisory Committee meeting, scheduled for Feb 10, has been postponed due to bad weather conditions in the Washington region. Cell Therapeutics is seeking FDA approval of Pixuvri for the treatment of relapsed or refractory aggressive non-Hodgkin’s Lymphoma (NHL) in patients who have not responded to other treatment options. The FDA usually follows panel recommendations to decide on the approvability of a particular drug. A final decision on Pixuvri would be taken by April 23. The postponement of the FDA’s committee meeting is not the end of problems at Cell Therapeutics. In an analysis for the committee, the FDA reviewers have raised ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/12/ctic-cell-therapeutics-drug-approval-delayed/27742/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Guards Againt Hostile Takeover</title>
		<link>http://www.stockbloghub.com/2009/12/29/ctic-cell-therapeutics-guards-againt-hostile-takeover/23823</link>
		<comments>http://www.stockbloghub.com/2009/12/29/ctic-cell-therapeutics-guards-againt-hostile-takeover/23823#comments</comments>
		<pubDate>Tue, 29 Dec 2009 19:23:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23823</guid>
		<description><![CDATA[In an attempt to guard itself against hostile takeover, Cell Therapeutics (CTIC) adopted a shareholder rights plan. The plan, to be effective from Jan 7, 2010, has been designed so that a potential buyer has to discuss any offer with Cell Therapeutics&#8217; board of directors before approaching the shareholders directly. Cell Therapeutics will give out options that would enable its shareholders to buy a fraction of a share of preferred stock in case of an acquisition of more than 20% of the company&#8217;s shares. In case of an acquisition, the board of Cell Therapeutics will decide whether to redeem the rights for common stock at a higher price. However, this will not be allowed for a potential acquirer. Cell Therapeutics is awaiting the US Food and Drug Administration&#8217;s (FDA) Oncologic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/29/ctic-cell-therapeutics-guards-againt-hostile-takeover/23823/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Reports Positive Data</title>
		<link>http://www.stockbloghub.com/2009/12/09/ctic-cell-therapeutics-reports-positive-data/22382</link>
		<comments>http://www.stockbloghub.com/2009/12/09/ctic-cell-therapeutics-reports-positive-data/22382#comments</comments>
		<pubDate>Thu, 10 Dec 2009 00:01:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22382</guid>
		<description><![CDATA[Cell Therapeutics (CTIC) announced positive data from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone in relapsed or refractory, aggressive non-Hodgkin&#8217;s lymphoma (NHL) patients who have not responded to 2 or more prior therapies. The data were presented at the 2009 American Society of Hematology (ASH) Annual Meeting. Analysis of the additional follow-up data supports the initial clinical trial results. We are pleased to note that for patients in follow-up period for at least 9 months from the end of treatment, pixantrone provided a 250% relative improvement in 1 year progression free survival or PFS (21% vs 6%) over comparator and a 115% increase in median overall PFS (5.6 months vs 2.6 months). Moreover, at 21 months post treatment, 14% of pixantrone patients remained free from disease ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/09/ctic-cell-therapeutics-reports-positive-data/22382/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Reports Earnings &#8211; Awaiting FDA Decision</title>
		<link>http://www.stockbloghub.com/2009/11/14/ctic-cell-therapeutics-reports-earnings-awaiting-fda-decision/20439</link>
		<comments>http://www.stockbloghub.com/2009/11/14/ctic-cell-therapeutics-reports-earnings-awaiting-fda-decision/20439#comments</comments>
		<pubDate>Sun, 15 Nov 2009 00:28:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20439</guid>
		<description><![CDATA[Cell Therapeutics’ (CTIC) third quarter loss per share came in at 8 cents compared to a loss of $1.14 reported in the year ago period. The company does not have any marketed product at present; it derives revenues primarily in the form of license and contract revenues. Cell Therapeutics recorded revenues of $0.02 million compared to $2.6 million in the third quarter of 2009. Revenues in the year ago period consisted of product sales of Zevalin, which the company sold to Spectrum Pharmaceuticals earlier in 2009. Operating expenses during the quarter increased 32.5% to $27 million primarily on account of more than 150% increase in SG&#38;A expenses. Cell Therapeutics has started preparing for the launch of pixantrone in 2010 by recruiting key persons and conducting market research; which has pushed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/ctic-cell-therapeutics-reports-earnings-awaiting-fda-decision/20439/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Releases Encouraging Data for Pixantrone</title>
		<link>http://www.stockbloghub.com/2009/09/18/ctic-cell-therapeutics-releases-encouraging-data-for-pixantrone/15570</link>
		<comments>http://www.stockbloghub.com/2009/09/18/ctic-cell-therapeutics-releases-encouraging-data-for-pixantrone/15570#comments</comments>
		<pubDate>Fri, 18 Sep 2009 17:00:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15570</guid>
		<description><![CDATA[Yesterday, Cell Therapeutics (CTIC) released encouraging data from the 18-month follow-up clinical trial of pixantrone for the treatment of patients with advanced, relapsed or refractory, aggressive non-Hodgkin&#8217;s lymphoma (NHL). The original trial compared pixantrone with standard chemotherapy; the results of which were reported last November. The company completed filing its rolling New Drug Application (NDA) in June this year and has been assigned a Prescription Drug User Fee Act (PDUFA) date of Apr 23, 2010. The follow-up trial conducted over a period of 18 months found improved results for patients on pixantrone compared to the control group. Based on the parameters of complete response (25.7% vs. 7.1% in control group), overall response rate (40% vs. 14.3%) and progression free survival (5.6 months vs. 2.6 months), the pixantrone data were better ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/ctic-cell-therapeutics-releases-encouraging-data-for-pixantrone/15570/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics Fails to Impress</title>
		<link>http://www.stockbloghub.com/2009/09/08/ctic-cell-therapeutics-fails-to-impress/14608</link>
		<comments>http://www.stockbloghub.com/2009/09/08/ctic-cell-therapeutics-fails-to-impress/14608#comments</comments>
		<pubDate>Tue, 08 Sep 2009 23:26:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14608</guid>
		<description><![CDATA[We were disappointed to hear that the US Food and Drug Administration (FDA) has granted standard review status to Cell Therapeutics’ (CTIC) pixantrone for the treatment of relapsed and refractory non-Hodgkin’s lymphoma (NHL). The company completed filing its rolling New Drug Application (NDA) in June this year and asked for priority review. Priority review would have reduced the approval period by four months. Pixantrone, currently under a ten-month standard review, has been assigned a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010. NHL is a cancer that affects lymphocytes, a type of white blood cell that helps fight infection. Since pixantrone had already received fast-track status from the FDA, we were expecting a priority review for the drug. In June, Cell Therapeutics presented encouraging results from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/08/ctic-cell-therapeutics-fails-to-impress/14608/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Ends NSCLC Drug Enrollment</title>
		<link>http://www.stockbloghub.com/2009/09/02/nvs-novartis-ends-nsclc-drug-enrollment/14274</link>
		<comments>http://www.stockbloghub.com/2009/09/02/nvs-novartis-ends-nsclc-drug-enrollment/14274#comments</comments>
		<pubDate>Thu, 03 Sep 2009 01:19:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14274</guid>
		<description><![CDATA[Yesterday, patient enrollment (1200) for a phase III trial of ASA404, jointly developed by Novartis (NVS) and Antisoma for the treatment of non small-cell lung cancer (NSCLC) was completed. Novartis is conducting the trial as the development and commercialization partner (for ASA404) of Antisoma. The trial will be conducted to test the effectiveness of the drug as a first-line treatment for squamous and non-squamous NSCLC with results due in 2010 or early 2011. The company expects to file for approval in 2011 if the trial results are positive. In addition to this, Novartis will be conducting another study of the drug in previously treated patients. Lung cancer kills 1.3 million people a year and is one of the leading causes of cancer death across the world. NSCLC accounting for about ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/nvs-novartis-ends-nsclc-drug-enrollment/14274/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CTIC) Cell Therapeutics&#8217; Drug Accepted For Review at FDA</title>
		<link>http://www.stockbloghub.com/2009/08/26/ctic-cell-therapeutics-drug-accepted-for-review-at-fda/13498</link>
		<comments>http://www.stockbloghub.com/2009/08/26/ctic-cell-therapeutics-drug-accepted-for-review-at-fda/13498#comments</comments>
		<pubDate>Wed, 26 Aug 2009 20:27:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cell Therapeutics Inc]]></category>
		<category><![CDATA[CTIC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13498</guid>
		<description><![CDATA[We are pleased to hear that the US Food and Drug Administration (FDA) accepted and filed for review Cell Therapeutics’ (CTIC) New Drug Application (NDA). The company is seeking FDA approval (NDA filed in June 2009) for pixantrone for the treatment of relapsed and refractory non-Hodgkin’s lymphoma (NHL). Though an action date is yet to be published, the company expects the FDA to take a final decision regarding the review status by Sept 4. Earlier in June, Cell Therapeutics presented encouraging results from a phase III trial of pixantrone. Although the efficacy data for pixantrone were encouraging, we are concerned about its side effects. While, neutropenia was 41.2% for pixantrone versus 19.4% for comparator, leukopenia was 23.5% for pixantrone versus 4.5% for comparator. Although the grade 3, 4 cardiac disorder ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/26/ctic-cell-therapeutics-drug-accepted-for-review-at-fda/13498/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

